CVR number 30177339
Industry 75.0000 Veterinary activities

OVERGADES DYREKLINIK ODENSE ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  7.3% 4.4% 4.2% 8.7% 11.9%  
Credit score (0-100)  33 46 48 27 20  
Credit rating  BBB BBB BBB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  3,946 4,204 4,508 4,789 4,945  
EBITDA  905 951 1,028 971 1,169  
EBIT  759 638 677 633 863  
Pre-tax profit (PTP)  712.0 580.1 582.9 553.4 792.1  
Net earnings  553.2 452.0 454.4 431.1 608.7  
Pre-tax profit without non-rec. items  712 580 583 553 792  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  2,360 2,641 2,475 2,191 1,754  
Shareholders equity total  804 703 707 684 735  
Interest-bearing liabilities  938 1,904 2,063 0.0 0.0  
Balance sheet total (assets)  3,038 3,759 3,882 3,385 2,788  
Net Debt  933 1,362 1,173 -571 -465  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  3,946 4,204 4,508 4,789 4,945  
Gross profit growth  25.0% 6.5% 7.2% 6.2% 3.3%  
Employees  11 11 12 12 10  
Employee growth %  27.9% 0.0% 9.1% 0.0% -16.7%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,038 3,759 3,882 3,385 2,788  
Balance sheet change%  66.6% 23.7% 3.3% -12.8% -17.6%  
Added value  905.4 950.8 1,027.9 983.8 1,168.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  1,752 -31 -517 -622 -743  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  19.2% 15.2% 15.0% 13.2% 17.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  31.2% 18.8% 17.7% 17.4% 28.1%  
ROI %  52.4% 28.3% 24.5% 35.1% 110.5%  
ROE %  75.0% 59.9% 64.4% 62.0% 85.8%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  26.5% 18.7% 18.2% 20.2% 26.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  103.1% 143.2% 114.1% -58.9% -39.8%  
Gearing %  116.6% 270.7% 291.9% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  7.6% 4.1% 4.8% 7.7% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.2 0.3 0.4 0.3 0.3  
Current Ratio  0.3 0.5 0.5 0.4 0.5  
Cash and cash equivalent  5.0 542.2 890.0 571.5 464.6  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -1,531.7 -1,259.8 -1,159.7 -1,498.0 -1,015.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  82 86 86 82 117  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  82 86 86 81 117  
EBIT / employee  69 58 56 53 86  
Net earnings / employee  50 41 38 36 61